{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T15:15:56Z","timestamp":1779376556800,"version":"3.53.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T00:00:00Z","timestamp":1744416000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T00:00:00Z","timestamp":1744416000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Natural Science Foundation of Zhejiang","award":["LY24C050001"],"award-info":[{"award-number":["LY24C050001"]}]},{"DOI":"10.13039\/501100020738","name":"K. C. Wong Magna Fund in Ningbo University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100020738","id-type":"DOI","asserted-by":"crossref"}]},{"name":"General Surgery Clinical Key Specialty Construction Project of Zhejiang Province","award":["2023-SZZ"],"award-info":[{"award-number":["2023-SZZ"]}]},{"name":"Project of Zhejiang Medical and Health Platform Plan","award":["2022KY1079"],"award-info":[{"award-number":["2022KY1079"]}]},{"name":"Ningbo Public Welfare Science & Technology Major Project","award":["2021S106"],"award-info":[{"award-number":["2021S106"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-02216-9","type":"journal-article","created":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T21:22:00Z","timestamp":1744492920000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Analysis and identification of PTBP2 as an oncogene in hepatocellular carcinoma"],"prefix":"10.1007","volume":"16","author":[{"given":"Yuxuan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengguang","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,12]]},"reference":[{"key":"2216_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"2216_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"2216_CR3","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","volume":"18","author":"DQ Huang","year":"2021","unstructured":"Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2021;18:223\u201338.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2216_CR4","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.08.024","author":"F Kanwal","year":"2018","unstructured":"Kanwal F, Kramer JR, Mapakshi S, Natarajan Y, Chayanupatkul M, Richardson PA, Li L, Desiderio R, Thrift AP, Asch SM, Chu J, El-Serag HB. Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease. Gastroenterology. 2018. https:\/\/doi.org\/10.1053\/j.gastro.2018.08.024.","journal-title":"Gastroenterology"},{"key":"2216_CR5","first-page":"2135","volume":"21","author":"AG Singal","year":"2023","unstructured":"Singal AG, Kudo M, Bruix J. Breakthroughs in hepatocellular carcinoma therapies. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2023;21:2135\u201349.","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"key":"2216_CR6","doi-asserted-by":"publisher","first-page":"e312","DOI":"10.1016\/S1470-2045(23)00186-9","volume":"24","author":"A Vitale","year":"2023","unstructured":"Vitale A, Cabibbo G, Iavarone M, Vigan\u00f2 L, Pinato DJ, Ponziani FR, Lai Q, Casadei-Gardini A, Celsa C, Galati G, Gambato M, Crocetti L, Renzulli M, Giannini EG, Farinati F, Trevisani F, Cillo U. Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept. Lancet Oncol. 2023;24:e312\u201322.","journal-title":"Lancet Oncol"},{"key":"2216_CR7","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","volume":"19","author":"JM Llovet","year":"2022","unstructured":"Llovet JM, Castet F, Heikenwalder M, Maini MK, Mazzaferro V, Pinato DJ, Pikarsky E, Zhu AX, Finn RS. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol. 2022;19:151\u201372.","journal-title":"Nat Rev Clin Oncol"},{"key":"2216_CR8","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41575-022-00704-9","volume":"20","author":"C Yang","year":"2023","unstructured":"Yang C, Zhang H, Zhang L, Zhu AX, Bernards R, Qin W, Wang C. Evolving therapeutic landscape of advanced hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2023;20:203\u201322.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2216_CR9","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.jhep.2023.03.003","volume":"79","author":"L Rimassa","year":"2023","unstructured":"Rimassa L, Finn RS, Sangro B. Combination immunotherapy for hepatocellular carcinoma. J Hepatol. 2023;79:506\u201315.","journal-title":"J Hepatol"},{"key":"2216_CR10","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1002\/cac2.12345","volume":"42","author":"K Cheng","year":"2022","unstructured":"Cheng K, Cai N, Zhu J, Yang X, Liang H, Zhang W. Tumor-associated macrophages in liver cancer: from mechanisms to therapy. Cancer Commun. 2022;42:1112\u201340.","journal-title":"Cancer Commun"},{"key":"2216_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231911363","author":"A Rizzo","year":"2022","unstructured":"Rizzo A, Ricci AD. Challenges and future trends of hepatocellular carcinoma immunotherapy. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms231911363.","journal-title":"Int J Mol Sci"},{"key":"2216_CR12","doi-asserted-by":"publisher","first-page":"3689","DOI":"10.3390\/cancers16213689","volume":"16","author":"TK Sahin","year":"2024","unstructured":"Sahin TK, Ayasun R, Rizzo A, Guven DC. Prognostic value of neutrophil-to-eosinophil ratio (NER) in cancer: a systematic review and meta-analysis. Cancers. 2024;16:3689.","journal-title":"Cancers"},{"key":"2216_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12111788","author":"A Rizzo","year":"2022","unstructured":"Rizzo A, Ricci AD, Brandi G. Trans-arterial chemoembolization plus systemic treatments for hepatocellular carcinoma: an update. J Personal Med. 2022. https:\/\/doi.org\/10.3390\/jpm12111788.","journal-title":"J Personal Med"},{"key":"2216_CR14","first-page":"624","volume":"31","author":"DC Guven","year":"2023","unstructured":"Guven DC, Erul E, Kaygusuz Y, Akagunduz B, Kilickap S, De Luca R, Rizzo A. Immune checkpoint inhibitor-related hearing loss: a systematic review and analysis of individual patient data. Support Care Cancer Off J Multinatl Assoc Support Care Cancer. 2023;31:624.","journal-title":"Support Care Cancer Off J Multinatl Assoc Support Care Cancer"},{"key":"2216_CR15","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1080\/17425255.2021.2029405","volume":"17","author":"A Rizzo","year":"2021","unstructured":"Rizzo A, Santoni M, Mollica V, Logullo F, Rosellini M, Marchetti A, Faloppi L, Battelli N, Massari F. Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study. Expert Opin Drug Metab Toxicol. 2021;17:1455\u201366.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2216_CR16","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/nrn.2016.27","volume":"17","author":"CK Vuong","year":"2016","unstructured":"Vuong CK, Black DL, Zheng S. The neurogenetics of alternative splicing. Nat Rev Neurosci. 2016;17:265\u201381.","journal-title":"Nat Rev Neurosci"},{"key":"2216_CR17","doi-asserted-by":"publisher","first-page":"0033","DOI":"10.34133\/research.0033","volume":"6","author":"J Tang","year":"2023","unstructured":"Tang J, He J, Guo H, Lin H, Li M, Yang T, Wang H-Y, Li D, Liu J, Li L, Xia H, Zhuo Z, Miao L. PTBP2-mediated alternative splicing of IRF9 controls tumor-associated monocyte\/macrophage chemotaxis and repolarization in neuroblastoma progression. Research. 2023;6:0033.","journal-title":"Research"},{"key":"2216_CR18","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1093\/brain\/awp153","volume":"132","author":"HC Cheung","year":"2009","unstructured":"Cheung HC, Hai T, Zhu W, Baggerly KA, Tsavachidis S, Krahe R, Cote GJ. Splicing factors PTBP1 and PTBP2 promote proliferation and migration of glioma cell lines. Brain J Neurol. 2009;132:2277\u201388.","journal-title":"Brain J Neurol"},{"key":"2216_CR19","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.molmed.2023.07.001","volume":"29","author":"K Xu","year":"2023","unstructured":"Xu K, Wu T, Xia P, Chen X, Yuan Y. Alternative splicing: a bridge connecting NAFLD and HCC. Trends Mol Med. 2023;29:859\u201372.","journal-title":"Trends Mol Med"},{"key":"2216_CR20","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41571-020-0350-x","volume":"17","author":"SC Bonnal","year":"2020","unstructured":"Bonnal SC, L\u00f3pez-Oreja I, Valc\u00e1rcel J. Roles and mechanisms of alternative splicing in cancer\u2014implications for care. Nat Rev Clin Oncol. 2020;17:457\u201374.","journal-title":"Nat Rev Clin Oncol"},{"key":"2216_CR21","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s40364-023-00492-7","volume":"11","author":"Y-S Chang","year":"2023","unstructured":"Chang Y-S, Tu S-J, Chen H-D, Chung C-C, Hsu M-H, Chou Y-P, Lee Y-T, Yen J-C, Jeng L-B, Chang J-G. Whole genome and RNA sequencing analyses for 254 Taiwanese hepatocellular carcinomas. Biomarker Res. 2023;11:68.","journal-title":"Biomarker Res"},{"key":"2216_CR22","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1101\/gr.227181.117","volume":"28","author":"K-T Lin","year":"2018","unstructured":"Lin K-T, Ma WK, Scharner J, Liu Y-R, Krainer AR. A human-specific switch of alternatively spliced AFMID isoforms contributes to TP53 mutations and tumor recurrence in hepatocellular carcinoma. Genome Res. 2018;28:275\u201384.","journal-title":"Genome Res"},{"key":"2216_CR23","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1002\/hep.32195","volume":"75","author":"H-Z Zhou","year":"2022","unstructured":"Zhou H-Z, Li F, Cheng S-T, Xu Y, Deng H-J, Gu D-Y, Wang J, Chen W-X, Zhou Y-J, Yang M-L, Ren J-H, Zheng L, Huang A-L, Chen J. DDX17-regulated alternative splicing that produced an oncogenic isoform of PXN-AS1 to promote HCC metastasis. Hepatology. 2022;75:847\u201365.","journal-title":"Hepatology"},{"key":"2216_CR24","doi-asserted-by":"publisher","first-page":"4080","DOI":"10.1158\/0008-5472.CAN-23-0544","volume":"83","author":"T Su","year":"2023","unstructured":"Su T, Zhang N, Wang T, Zeng J, Li W, Han L, Yang M. Super enhancer-regulated LncRNA LINC01089 induces alternative splicing of DIAPH3 to drive hepatocellular carcinoma metastasis. Can Res. 2023;83:4080\u201394.","journal-title":"Can Res"},{"key":"2216_CR25","doi-asserted-by":"publisher","first-page":"W509","DOI":"10.1093\/nar\/gkaa407","volume":"48","author":"T Li","year":"2020","unstructured":"Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q, Li B, Liu XS. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020;48:W509\u201314.","journal-title":"Nucleic Acids Res"},{"key":"2216_CR26","doi-asserted-by":"publisher","first-page":"W214","DOI":"10.1093\/nar\/gkq537","volume":"38","author":"D Warde-Farley","year":"2010","unstructured":"Warde-Farley D, Donaldson SL, Comes O, Zuberi K, Badrawi R, Chao P, Franz M, Grouios C, Kazi F, Lopes CT, Maitland A, Mostafavi S, Montojo J, Shao Q, Wright G, Bader GD, Morris Q. The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function. Nucleic Acids Res. 2010;38:W214\u201320.","journal-title":"Nucleic Acids Res"},{"key":"2216_CR27","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1158\/0008-5472.CAN-17-0307","volume":"77","author":"T Li","year":"2017","unstructured":"Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, Li B, Liu XS. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Can Res. 2017;77:e108\u201310.","journal-title":"Can Res"},{"key":"2216_CR28","doi-asserted-by":"publisher","first-page":"W98","DOI":"10.1093\/nar\/gkx247","volume":"45","author":"Z Tang","year":"2017","unstructured":"Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45:W98.","journal-title":"Nucleic Acids Res"},{"key":"2216_CR29","doi-asserted-by":"publisher","first-page":"D956","DOI":"10.1093\/nar\/gkx1090","volume":"46","author":"SV Vasaikar","year":"2018","unstructured":"Vasaikar SV, Straub P, Wang J, Zhang B. LinkedOmics: analyzing multi-omics data within and across 32 cancer types. Nucleic Acids Res. 2018;46:D956\u201363.","journal-title":"Nucleic Acids Res"},{"key":"2216_CR30","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41423-020-00572-w","volume":"18","author":"B Ruf","year":"2021","unstructured":"Ruf B, Heinrich B, Greten TF. Immunobiology and immunotherapy of HCC: spotlight on innate and innate-like immune cells. Cell Mol Immunol. 2021;18:112\u201327.","journal-title":"Cell Mol Immunol"},{"key":"2216_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.775462","volume":"9","author":"X Hao","year":"2021","unstructured":"Hao X, Sun G, Zhang Y, Kong X, Rong D, Song J, Tang W, Wang X. Targeting immune cells in the tumor microenvironment of HCC: new opportunities and challenges. Front Cell Dev Biol. 2021;9: 775462.","journal-title":"Front Cell Dev Biol"},{"key":"2216_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22115801","author":"K Oura","year":"2021","unstructured":"Oura K, Morishita A, Tani J, Masaki T. Tumor immune microenvironment and immunosuppressive therapy in hepatocellular carcinoma: a review. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22115801.","journal-title":"Int J Mol Sci"},{"key":"2216_CR33","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, Hoang CD, Diehn M, Alizadeh AA. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12:453\u20137.","journal-title":"Nat Methods"},{"key":"2216_CR34","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41419-023-05636-z","volume":"14","author":"X Hong","year":"2023","unstructured":"Hong X, Ma N, Li D, Zhang M, Dong W, Huang J, Ci X, Zhang S. UBE2E2 enhances Snail-mediated epithelial-mesenchymal transition and Nrf2-mediated antioxidant activity in ovarian cancer. Cell Death Dis. 2023;14:100.","journal-title":"Cell Death Dis"},{"key":"2216_CR35","doi-asserted-by":"publisher","first-page":"233","DOI":"10.5483\/BMBRep.2014.47.4.140","volume":"47","author":"W Han","year":"2014","unstructured":"Han W, Wang L, Yin B, Peng X. Characterization of a novel posttranslational modification in polypyrimidine tract-binding proteins by SUMO1. BMB Rep. 2014;47:233\u20138.","journal-title":"BMB Rep"},{"key":"2216_CR36","doi-asserted-by":"publisher","first-page":"D1465","DOI":"10.1093\/nar\/gkad751","volume":"52","author":"Y Zhou","year":"2024","unstructured":"Zhou Y, Zhang Y, Zhao D, Yu X, Shen X, Zhou Y, Wang S, Qiu Y, Chen Y, Zhu F. TTD: therapeutic target database describing target druggability information. Nucleic Acids Res. 2024;52:D1465\u201377.","journal-title":"Nucleic Acids Res"},{"key":"2216_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/cells8121511","author":"M Massimi","year":"2019","unstructured":"Massimi M, Ragusa F, Cardarelli S, Giorgi M. Targeting cyclic AMP signalling in hepatocellular carcinoma. Cells. 2019. https:\/\/doi.org\/10.3390\/cells8121511.","journal-title":"Cells"},{"key":"2216_CR38","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1038\/leu.2009.94","volume":"23","author":"T Ikezoe","year":"2009","unstructured":"Ikezoe T, Yang J, Nishioka C, Takezaki Y, Tasaka T, Togitani K, Koeffler HP, Yokoyama A. A novel treatment strategy targeting polo-like kinase 1 in hematological malignancies. Leukemia. 2009;23:1564\u201376.","journal-title":"Leukemia"},{"key":"2216_CR39","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/nm1003","volume":"10","author":"EA Harrington","year":"2004","unstructured":"Harrington EA, Bebbington D, Moore J, Rasmussen RK, Ajose-Adeogun AO, Nakayama T, Graham JA, Demur C, Hercend T, Diu-Hercend A, Su M, Golec JMC, Miller KM. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med. 2004;10:262\u20137.","journal-title":"Nat Med"},{"key":"2216_CR40","doi-asserted-by":"publisher","first-page":"12104","DOI":"10.3390\/ijms232012104","volume":"23","author":"X Liu","year":"2022","unstructured":"Liu X, Shi Q, Choudhry N, Zhang T, Liu H, Zhang S, Zhang J, Yang D. The effect of circumscribed exposure to the pan-aurora kinase inhibitor VX-680 on proliferating euploid cells. Int J Mol Sci. 2022;23:12104.","journal-title":"Int J Mol Sci"},{"key":"2216_CR41","doi-asserted-by":"publisher","first-page":"3221","DOI":"10.1080\/15548627.2020.1851492","volume":"17","author":"P Luo","year":"2021","unstructured":"Luo P, Yan H, Du J, Chen X, Shao J, Zhang Y, Xu Z, Jin Y, Lin N, Yang B, He Q. PLK1 (polo like kinase 1)-dependent autophagy facilitates gefitinib-induced hepatotoxicity by degrading COX6A1 (cytochrome c oxidase subunit 6A1). Autophagy. 2021;17:3221\u201337.","journal-title":"Autophagy"},{"key":"2216_CR42","doi-asserted-by":"publisher","first-page":"188467","DOI":"10.1016\/j.bbcan.2020.188467","volume":"1875","author":"CA Raab","year":"2021","unstructured":"Raab CA, Raab M, Becker S, Strebhardt K. Non-mitotic functions of polo-like kinases in cancer cells. Biochimica Et Biophysica Acta Rev Cancer. 2021;1875:188467.","journal-title":"Biochimica Et Biophysica Acta Rev Cancer"},{"key":"2216_CR43","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.semcancer.2021.06.019","volume":"85","author":"L Yu","year":"2022","unstructured":"Yu L, Wei J, Liu P. Attacking the PI3K\/Akt\/mTOR signaling pathway for targeted therapeutic treatment in human cancer. Semin Cancer Biol. 2022;85:69\u201394.","journal-title":"Semin Cancer Biol"},{"key":"2216_CR44","first-page":"4832","volume":"13","author":"Y Li","year":"2023","unstructured":"Li Y, Zhu J, Yu Z, Zhai F, Li H, Jin X. Regulation of apoptosis by ubiquitination in liver cancer. Am J Cancer Res. 2023;13:4832\u201371.","journal-title":"Am J Cancer Res"},{"key":"2216_CR45","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s41420-024-02116-x","volume":"10","author":"Wu Xa","year":"2024","unstructured":"Xa Wu, Cao J, Wan X, Du S. Programmed cell death in hepatocellular carcinoma: mechanisms and therapeutic prospects. Cell Death Discov. 2024;10:356.","journal-title":"Cell Death Discov"},{"key":"2216_CR46","doi-asserted-by":"publisher","first-page":"968458","DOI":"10.3389\/fmolb.2022.968458","volume":"9","author":"C Chen","year":"2022","unstructured":"Chen C, Shang A, Gao Y, Huang J, Liu G, Cho WC, Li D. PTBPs: An immunomodulatory-related prognostic biomarker in pan-cancer. Front Mol Biosci. 2022;9:968458.","journal-title":"Front Mol Biosci"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02216-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-02216-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02216-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T21:22:02Z","timestamp":1744492922000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-02216-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,12]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2216"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-02216-9","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,12]]},"assertion":[{"value":"27 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research received approval from the Hospital's Committee for the Protection of Human Subjects. Additionally, the Ethics Committee of Ningbo University granted ethical clearance for the study (NBU-2022-123). We declare that this study was conducted on human beings and\/or human data in accordance with the Declaration of Helsinki. The animal experimentation protocol was reviewed and approved by the Animal Ethics and Welfare Committee of the Ningbo University (NBU20210057).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed Consent was obtained from all the participants involved in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"520"}}